Welcome to our dedicated page for Varex Imaging news (Ticker: VREX), a resource for investors and traders seeking the latest updates and insights on Varex Imaging stock.
Varex Imaging Corporation reports developments tied to its X-ray imaging component business, including X-ray tubes, digital detectors, connecting devices, imaging software and industrial X-ray systems. Company news commonly covers results from its Medical and Industrial segments, demand trends in CT products, cargo security systems and photon counting detectors, and updates for products used by global OEM manufacturers in medical, industrial and security imaging applications.
Recurring announcements also include earnings releases and conference calls, investor conference participation, and capital-structure actions such as the refinancing of secured debt and redemption of senior secured notes.
Varex (Nasdaq: VREX) reported Q2 fiscal 2026 results: revenue $216M, GAAP gross margin 34%, non-GAAP gross margin 34%, GAAP operating margin 7%, non-GAAP operating margin 9%, GAAP loss $0.19 per share and non-GAAP income $0.21 per share.
Cash, cash equivalents and marketable securities were $88M at quarter end (down from $155M). Full‑year revenue guidance is $860M–$880M with non‑GAAP EPS of $0.80–$1.00. Q3 revenue guidance is $210M–$225M and non‑GAAP EPS $0.15–$0.30.
Varex (Nasdaq: VREX) will report unaudited fiscal 2026 second quarter results after market close on May 7, 2026, followed by a conference call at 3:00 pm Mountain Time. The call will be webcast live and archived on the company investor website.
Replay access runs from May 7 through May 21, 2026, with domestic and international dial‑in numbers and a replay access code available.
Varex Imaging (Nasdaq: VREX) closed a new secured $490 million Credit Facility dated March 13, 2026, maturing March 13, 2031, composed of a $350M term loan, $100M revolver and $40M delayed draw term loan.
The company redeemed $368M of 7.875% senior secured notes using about $42M cash and entered an interest rate swap fixing SOFR at 3.65%, expected to cut annualized cash interest expense by more than $7M.
Varex (Nasdaq: VREX) management will present at two upcoming investor conferences in March 2026: Oppenheimer’s 36th Annual Healthcare, MedTech & Services Virtual Conference and the Sidoti Small Cap Virtual Conference. Webcasts are available via the listed conference links or on Varex's investor website.
Varex Imaging (Nasdaq: VREX) issued a conditional full redemption notice for all outstanding 7.875% senior secured notes due Oct 15, 2027, with a Redemption Date of March 16, 2026 subject to a new credit facility closing.
The outstanding principal is $368,000,000. The redemption price equals 101.969% plus accrued interest, totaling $1,052.72125 per $1,000 principal. The Company intends to fund the payment with proceeds of the New Financing and cash on hand; the redemption is conditional on the Financing Condition.
Varex (Nasdaq: VREX) reported Q1 FY2026 revenue of $210 million, up 5% year-over-year, with Medical at $145 million and Industrial at $65 million. GAAP net income was $0.05 per diluted share; non-GAAP EPS was $0.19. Cash outflow from operations was $16 million; cash and marketable securities totaled $126 million. Q2 guidance: revenue $210–225 million and non-GAAP EPS $0.15–0.25.
Varex Imaging (Nasdaq: VREX) will report unaudited results for Q1 fiscal 2026 after market close on Tuesday, February 10, 2026. A conference call will follow at 3:00 pm Mountain Time the same day and will be webcast live at the company’s investor site.
Investors can join by phone at 877-524-8416 (U.S.) or 412-902-1028 (non-U.S.). A replay will be available from February 10–24, 2026 with access code 13758188. Varex is headquartered in Salt Lake City and employs ~2,400 people worldwide; it designs and manufactures X-ray imaging components and systems for medical, industrial and security uses.
Varex (Nasdaq: VREX) said company management will present at the CJS Securities 26th Annual New Ideas for the New Year Virtual Conference on Wednesday, January 14, 2026 at 3:50pm ET. The presentation will be available via webcast and can be accessed on Varex’s investor website at www.vareximaging.com/news.
Varex (Nasdaq: VREX) reported Q4 FY2025 and full-year results on November 18, 2025. Q4 revenue was $229M (+11% YoY); Medical $152M (+5% YoY) and Industrial $77M (+25% YoY). Q4 non-GAAP gross margin was 34% and non-GAAP EPS was $0.37 (vs $0.19 a year ago). FY2025 revenue was $845M (+4% YoY); non-GAAP EBITDA rose 37% to $122M and non-GAAP EPS was $0.90 (+73%). Cash and equivalents were $155M at year-end after paying principal on convertible notes on June 2, 2025. Q1 FY2026 guidance: revenue $200–$215M, non-GAAP EPS $0.05–$0.25. Conference call held Nov 18, 2025.
Varex Imaging (Nasdaq: VREX) will report unaudited financial results for the fourth quarter and fiscal year 2025 after market close on Tuesday, November 18, 2025. A conference call and live webcast will follow at 3:00 PM Mountain Time that day.
Investors can join the live webcast at www.vareximaging.com/investor-relations/ or by phone at 877-524-8416 (U.S.) and 412-902-1028 (non-U.S.). The call webcast will be archived and a replay will be available from November 18 through December 2, 2025 at 877-660-6853 (U.S.) or 201-612-7415 (non-U.S.) using access code 13756256.
Varex designs and manufactures X-ray imaging components and systems and is headquartered in Salt Lake City, employing about 2,300 people globally.